Page last updated: 2024-10-31

neostigmine and Cancer of Pelvis

neostigmine has been researched along with Cancer of Pelvis in 1 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Research Excerpts

ExcerptRelevanceReference
"Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia."8.98Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature. ( Jiang, H; Li, S; Luo, A; Zhang, X; Zhao, Y, 2018)
"Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia."4.98Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature. ( Jiang, H; Li, S; Luo, A; Zhang, X; Zhao, Y, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, X1
Jiang, H1
Li, S1
Luo, A1
Zhao, Y1

Reviews

1 review available for neostigmine and Cancer of Pelvis

ArticleYear
Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature.
    Medicine, 2018, Volume: 97, Issue:14

    Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Adult; Cholinesterase Inhibitor

2018